AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04455750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT04455750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT04455750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT04455750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given SC
Study NCT04455750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC
Study NCT04455750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04455750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04998552 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cyberknife
Description: 5-10 Gy/fraction.Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
Study NCT04748757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human annexin A5
Description: recombinant human annexin A5, manufactured as SY-005
Study NCT04748757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 50 ml
Study NCT06504758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Retraining Program
Description: * 1st to 5th week - Breathing Retraining 10 repetitions (Pursed Lip Breathing, Diaphragmatic Breathing)~* Two days / a week The total duration of 5 weeks.
Study NCT06504758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Exerises Program (Stretching and Strengthening Exercises)
Description: * TheraBand® or Free Weight~* 1st week - neck isometrics, chin tuck, SCM - upper trapezius - pectoral major stretching, scapular retraction without weight, rowing with yellow TheraBand®, wall squat / mini squat (5 repetitions - 15 second hold for stretching exercises, 10 repetitions for strengthening exercises)~* 2nd and 3rd week - same exercises (5 repetitions - 15 second hold for stretching exercises, 15 repetitions for strengthening exercises)~* 4th and 5th week - same exercises (10 repetitions - 15 second hold for stretching exercises, 20 repetitions for strengthening exercises)~* Two days / a week,The total duration of 5 weeks
Study NCT05529043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MINISTOP app
Description: The MINISTOP app is a behavioural change program aiming to promote healthier diet and physical activity behaviours in pre-school children. The program consists of features such as information, monitoring and feedback (dietary variables, physical activity, and screen time) and it is built around 13 themes. The participants will have access to the app for 12-months.
Study NCT05529043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINISTOP Plus Program
Description: Consists of the MINISTOP app and the Community Group Mini. The Community Group Mini consists of group activities to promote physical activity for both children and parents. The Community Group Mini will meet once per week in different playgrounds and nature reserves and will be organized by a trained group leader.
Study NCT05484518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Method of Levels Therapy
Description: Method of Levels (MOL) is a therapy that is the direct application of Perceptual Control Theory (PCT) (Powers, 2008) which proposes that psychological distress results from a person's reduced control over important life goals. A conflict between two or more goals can occur outside of a person's awareness (Carey, Mansell \& Tai, 2014) and the achievement of one goal leaves the other incompatible goal unachievable, leading to distress (Mansell, 2012). MOL therapy aims to help people develop awareness of important goals and conflicts between them, to increase their chances of developing potential solutions. Conflict can be resolved through reorganisation; a mechanism through which random change is continuously generated until control is restored (Tai, 2016).~Therapy uses a questioning style to help clients bring their attention to their problems long enough for them to restore control. In practice clients choose the number, frequency and duration of therapy sessions
Study NCT03959566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutezolid
Description: Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.
Study NCT03959566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.
Study NCT03959566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.
Study NCT03959566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution
Description: Midazolam will be administered as per probe drug use in a single dose of 2 mg at day -1 and day 14 to assess the potential of sutezolid for CYP 459 3A4 enzyme induction, as measured by its influence on the ratio of AUCs of the CYP 3A4 probe drug
Study NCT05364931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide
Description: Cotadutide administered subcutaneously once daily
Study NCT04455750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04455750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05364931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously once daily
Study NCT05122273 — intervention group
Intervention type: DEVICE
Intervention: Stella BIO
Description: Individually planned therapeutic procedures, using, among others, the concept of EMG biofeedback
Study NCT04671225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Groups Psychoeducation
Description: Manual-structured group psychoeducation with 8 sessions of 90 minutes over the course of 8 weeks (at one session per week). The manual is centred on behavioural principles from social education and self-regulation philosophies. All groups will have 6-8 participants and two health professionals to conduct the sessions; a psychiatric nurse and either a psychologist or a psychiatric resident. Patients will be offered to invite their relatives for 2-3 psychoeducation-days for relatives.
Study NCT04671225 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting-list
Description: Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
Study NCT05199298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala Activity-Based Breastfeeding Program
Description: Training modules for breastfeeding and Maternal -infant attachment will be implemented with pregnant women in the study group at 32-36 weeks of gestation. The training will be explained by the researchers by shooting a video. In addition, for each week, mandala drawings will be videotaped by the researcher who received mindfulness-based art therapy training and will be sent to the Whatsapp accounts of the pregnant women. t 36 weeks of gestation, the Prenatal Attachment Scale and Spielberger State Anxiety Inventories will be sent to mothers as Google forms. The mother will be called 24 hours after the birth and the situation of having a problem with breastfeeding will be determined. In the first week, in the first and second months after the birth, questionnaire forms and online questionnaires will be applied to the mothers, apart from the follow-up and counseling in the postpartum 2nd month, the posttests of the scales
Study NCT05113472 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pfizer-BioNTech COVID-19 vaccine
Description: Patients who were administered any dose of the Pfizer-BioNTech COVID-19 vaccine.
Study NCT05891314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botox Injectable Product
Description: one group will have botox injection in the internal sphincter
Study NCT05891314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal sphincterotomy
Description: this group will have internal sphincterotomy
Study NCT05651451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser acupuncture
Description: 24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point
Study NCT05651451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: energy-restricted diet
Description: All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
Study NCT06039826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.
Study NCT06039826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol
Description: Administered orally
Study NCT06039826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone
Description: Administered orally
Study NCT04861467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: IV
Study NCT04998552 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cyberknife
Description: 5-10 Gy/fraction.Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
Study NCT05974033 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stenting plus medical therapy
Description: Patients randomized to intervention group received the percutaneous transluminal balloon angioplasty with stenting within 5 days after randomization, and loading dose of aspirin and clopidogrel was allowed. Received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after procedure.
Study NCT05974033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy alone
Description: Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.
Study NCT04503681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced compassion video
Description: Added five additional sentences to the standard introduction video. Those five sentences were compassion-focused statements. The compassionate statements added to the enhanced compassion video were based on the results of a recent systematic review of clinician compassionate behaviors, which found incorporating statements of support, acknowledgement, patient's perspective, emotion naming, and validation increased patient perception of compassion.
Study NCT04503681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard introduction video
Description: Standard introduction video sent to a new patient via email introducing the new patient to the cancer center prior to the initial consultation.
Study NCT05919680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-6179 Part A
Description: Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks
Study NCT05919680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-6179 Part B
Description: Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks
Study NCT05919680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched Placebo
Description: Matched placebo for administration in Part A or Part B
Study NCT06176872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Computed Tomography Angiography
Description: Non-invasive imaging of the heart, the greater vessels and the coronary arteries using computed tomography.
Study NCT04139577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
Study NCT04984876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ligelizumab
Description: Subcutaneous injection once every 4 weeks
Study NCT04334408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fremanezumab
Description: Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
Study NCT04334408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fremanezumab
Description: Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
Study NCT04334408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
Study NCT04334408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
Study NCT04958005 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Enzim linked immunoabsorbant assay
Study NCT06207994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow TR
Description: The width of the PRICO SpO2 TR is set to 3% SpO2.
Study NCT06141486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frexalimab
Description: SAR441344 Solution for IV infusion
Study NCT06141486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for IV infusion
Study NCT06141486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRI contrast-enhancing agents
Description: IV, as per respective label
Study NCT04984876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection once every 4 weeks
Study NCT05557552 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standar thoracic RT dose
Description: All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with standard dose thoracic radiotherapy of 60 Gy/30Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
Study NCT05557552 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: decreased thoracic RT dose
Description: All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with decreased thoracic radiotherapy of 50Gy/25Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
Study NCT06581497 — intervention group
Intervention type: DRUG
Intervention: ICIs
Description: ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines.
Study NCT06581497 — intervention group
Intervention type: PROCEDURE
Intervention: ICIs+MWA
Description: ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines. All patients, except for those enrolled in ICIs, should also undergo MWA treatment.
Study NCT05649722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil Inhalation Powder
Description: Oral inhalation using a capsule-based dry powder inhaler device.
Study NCT05649722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo inhalation using a capsule-based dry powder inhaler device.
Study NCT06207994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shifted TR
Description: The lower and the upper limits of the PRICO SpO2 TR are increased by 1% SpO2.
Study NCT05165940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Care Coordination Treatment as usual with a VA mental health treatment coordinator
Study NCT05165940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Health Services Intervention
Description: The experimental care coordination intervention begins with a 60-minute in-person session and continues with regular, brief contacts between the Veteran and clinician. During the first session, the clinician and Veteran will (1) discuss the Veteran's beliefs about their presenting problem; (2) collaboratively identify SMART goals; (3) discuss treatment options; (4) use shared decision-making to match treatment to SMART goals; (5) develop criteria to evaluate treatment progress; and (6) manage treatment expectations. During follow-up sessions, the clinician and Veteran will reflect on treatment progress, make appropriate updates to SMART goals, and re-evaluate barriers to CPT or PE.
Study NCT05858671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fenugreek Seed Tea
Description: Fenugreek seeds will be delivered at a dose of 5g/day, drunk as a tea (2.5g/per tea bag), p.o. twice a day at a 12-hour interval) for 8 weeks (56 days). The tea bags will be brewed in a cup (200ml) of boiled hot water for 10 minutes before drinking. This will be self-administered by the subjects, twice a day at a 12-hour interval.
Study NCT05858671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Black Tea
Description: A control black tea (2.5g/bag), self-administered by the subjects, twice in a day at a 12-hour interval.
Study NCT06528743 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases.
Description: Patients will receive RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases. Enrolled patients will receive a fractionation scheme with increasing break length.
Study NCT05901051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan
Description: Potassium competitive acid blocker
Study NCT05901051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotics for H. pylori eradication
Study NCT05291988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive S2S education
Study NCT05291988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test
Description: Receive FIT kit
Study NCT05291988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary Studies
Study NCT05781347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Energy to the LES (Stretta Procedure)
Description: The Stretta procedure is an endoscopic treatment performed under general anesthesia. It utilizes radiofrequency (RF) energy delivered to the lower esophageal sphincter (LES) and the gastric cardia to enhance the antireflux barrier.
Study NCT05752903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine-propofol
Description: 1 microgram/kg dexmedetomidine+2.5 mg/kg propofol intravenous (IV) bolus, 0.5 microgram g/kg/h dexmedetomidine+2.5 mg/kg/h propofol infusion
Study NCT05752903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine-Propofol
Description: 1 mg/kg ketamine+2.5 mg/kg propofol iv bolus, 0.25 mg/kg/h ketamine+2.5mg/kg/h propofol infusion
Study NCT05855850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway H4-Coil Deep TMS System
Description: Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H4-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
Study NCT05855850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway H7-Coil Deep TMS System
Description: Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H7-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
Study NCT05875090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glaucoma Screening
Description: Non-invasive diagnostic techniques will screen subjects in primary care setting for the existence of Glaucoma and categorised them in a binary system: referrable vs non-referrable to a Hospital-based Glaucoma Clinic